UK HealthCare's Gill Heart Institute and The Christ Hospital in Cincinnati have partnered to test a new treatment for adults with congenital heart disease. The COMPASSION Trial will test the efficacy of the Sapien 3 valve as a replacement for a diseased pulmonary valve. The Sapien 3 has already been approved for replacement of the aortic valve. “This study offers a revolutionary new treatment for patients with adult congenital heart disease who would otherwise be facing at least a second surgical procedure,” said Dr.

 

 

 

Left to right: Drs. Jacilyn Brainard, Jack Kupies, Mohammed Issa, Eduardo Chacon, Baher Guirguis and Daniel Ramsey

A 2016 UK College of Medicine graduate was awarded second place in the annual scholarship competition of the International Congress of Surgeons, (ICS), United States Section, over a weekend in early June.

The University of Kentucky (UK) Center of Excellence in Rural Health (CERH) is one of 38 community organizations to receive funding from the Centers for Medicare & Medicaid Services (CMS) to help enroll eligible children in Medicaid and CHIP as part of the Connecting Kids to Coverage campaign.

In December 1968, a widowed mother from Knoxville, Tennessee, arrived with her two sons, daughter and nephew at the University of Kentucky's pediatric clinic.

The four children were afflicted with severe intellectual impairment, presenting at the clinic with IQs of 10 or lower. The children showed normal development at birth, but during the first year of life experienced neurological deficiencies that rendered them unable to speak or walk. In the second and third years of life, the children were stricken with intense epileptic seizures.

All heart attacks are serious, but one type – called STEMI — is particularly deadly. “A STEMI, or ST Segment Elevation Myocardial Infarction, means an artery to the heart is 100 percent blocked, which is associated with a much higher short-term risk of death or disability compared to other types of heart attack,” Dr.
The University of Kentucky has signed a membership agreement to join the TriNetX network, a leader in international clinical research networks, in order to optimize clinical trial design and advance clinical research for UK programs. Pharmaceutical researchers will gain access to UK's clinical data in real time through TriNetX's proprietary network of health care institutions representing more than 37 million patients in the US and Europe to support clinical study and protocol design, site selection, and patient recruitment across a range of therapeutic areas and development stages. UK w

The University of Kentucky’s Division of Plastic Surgery retained possession of the coveted Glancy Cup for a second consecutive year and for the third time in four years, when Dr. William North, a fifth-year resident, was named winner of the prestigious Glancy Award at the 59th annual scientific meeting of the Southeastern Society of Plastic and Reconstructive Surgeons (SESPRS).

The Glancy Award recognizes residents for excellence in Plastic Surgery research.

New NHLBI Policy: Investigator-Initiated Multi-Site Clinical Trials

Notice Number: NOT-HL-16-321 

Release Date:  June 14, 2016